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Background
Cancer cachexia is a syndrome associated with malignant 
tumor  disease  defined  by  weight  loss,  asthenia  and 
anorexia. Up to half of all cancer patients are affected, 
leading  to  increased  morbidity  and  poor  prognosis  [1] 
with  perhaps  20%  of  cancer  deaths  being  related  to 
cachexia rather than direct tumor effects [2]. Cachectic 
patients  suffer  loss  of  both  muscle  mass  and  adipose 
tissue (with comparative sparing of visceral protein) and 
this tissue loss appears resistant to nutritional support 
[3,4]. A PubMed analysis indicates that almost one-third of 
documents discussing cancer cachexia are review articles, 
highlighting the need for more primary investigations to 
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syndrome in patients. Furthermore, most molecular hypo  -
theses have been generated using pre-clinical models or 
reflect biochemical concepts [5] and there has been little 
progress  in  relating  these  potential  mechanisms  to 
changes observed in the patient.
Muscle mass is maintained by physical activity, reflect-
ing a balance between protein synthesis and degrada  tion. 
Intracellular  protein  breakdown  involves  the  ubiquitin 
proteasome  pathway  (UPP)  and  the  autophagy  (lyso-
somal),  caspase,  cathepsin  and  the  calcium-dependent 
calpain pathways. The individual prominence of each of 
these  pathways  in  muscle  wasting  conditions  is  still 
debated. Many of the molecular signaling pathways that 
are postulated to contribute to muscle atrophy in pre-
clinical models mediate their effects through activation 
of the UPP [6]. Identification of two muscle-specific E3 
ubiquitin  ligases,  MuRF-1  and  MAFbx/atrogin-1,  in  a 
large number of animal models of atrophy [7,8] has been 
used to provide an argument for a major contribution of 
the UPP in muscle wasting, such that these genes are now 
measured  as  surrogate  indicators  of  UPP  activation.  It 
should  be  kept  in  mind  that  active  tissue  remodeling, 
even with net protein accretion, may well rely partly on 
the protein degradation pathways and, as such, they may 
not represent logical surrogates for commenting on net 
protein degradation.
In humans, reduced levels of phosphorylated (inactive) 
FOXO3a have been observed in the skeletal muscle of 
cachectic compared with non-cachectic cancer patients, 
but an unexplained twofold reduction in the amount of 
FOXO1 and FOXO3a was also observed [9], making the 
data  challenging  to  interpret.  FOXO3  also  appears  to 
induce  expression  of  autophagy-related  genes  [10-13], 
suggesting a link between the lysosomal and proteasomal 
systems. However, there is also evidence that the UPP is 
first activated with increasing weight loss then declines 
as the disease severity progresses [14]. This suggests that 
UPP is a marker of protein turn-over rather than wasting 
per se (with turn-over increasing as the muscle weakens, 
but only while the patient continues to be ambulatory) 
or  that  UPP  proteins  are  not  reliable  biomarkers. 
Further  more,  recent  data  indicates  a  dissociation 
between  protein  dynamics  in  vivo  and  activation  or 
expression  of  the  UPP-related  signaling  molecules  in 
human skeletal muscle [15]. Overall, it is not clear what 
regulates  muscle  mass  in  vivo  nor  is  it  clear  to  what 
extent protein degradation contributes over inhibition of 
protein  syn  thesis  [15,16].  Given  the  paucity  of  data 
derived from cancer cachexia patients, including study 
of the UPP and autophagy systems, we sought to carry 
out both targeted and global molecular profiling in the 
skeletal muscle of cancer patients and relate our findings 
to clinical status.
Methods
Men and non-pregnant women over 18 years of age were 
recruited to the study from two separate centers. Written 
informed  consent  was  obtained  from  all  subjects  and 
ethical approval received from Lothian Research Ethics 
Committee (UK) and the Regional Ethics Committee in 
Stockholm  (Sweden).  Participating  patients  had  a 
diagnosis  of  upper  gastrointestinal  cancer  (esophageal, 
gastric,  pancreatic)  and  were  undergoing  surgery  with 
the  intent  of  resection  of  the  primary  tumor.  A  small 
number  of  weight  stable  (WS)  patients  undergoing 
surgery for benign, non-inflammatory conditions (n = 7) 
were also included in the analysis. In center 1 (Edinburgh, 
UK) a fasting venous blood sample was taken and serum 
C-reactive  protein  measured  as  a  marker  of  systemic 
inflammation (SI). Body mass index (BMI) and mid-arm 
muscle  circumference  were  calculated.  Clinical  details 
and degree of weight loss from self-reported pre-illness 
stable weight were recorded. A weight loss ≥5% identified 
weight-losing (WL) cancer patients as opposed to weight 
stable  (WS)  individuals.  A  serum  C-reactive  protein 
≥5  mg/l  was  used  to  define  the  presence  of  SI.  For 
patients from center 2 (Stockholm, Sweden) weight and 
self-reported change in weight over time were recorded. 
Rate of weight loss was therefore used in these subjects. 
Due to the small number of controls (otherwise con  sidered 
as non-cancer patients but with other co-morbidities) and 
the lack of detailed knowledge of their physical capacity, 
the  primary  analysis  strategy  was  chosen  to  generate 
molecular changes that varied with the severity of weight 
loss in patients in center 1 and validate such changes in the 
independent cohort from center 2 using more than one 
muscle  type.  This  strategy  was  devised  to  provide  a 
stringent test of the molecular changes, as the conclusions 
are  based  on  a  relatively  large  number  of  patients  with 
otherwise similar clinical characteristics.
All biopsies were taken at the start of open abdominal 
surgery. In center 1, the edge of the rectus abdominis was 
exposed  and  a  1-cm3  specimen  removed  using  sharp 
dissection. The biopsy was snap frozen in liquid nitrogen 
and  stored  at  -80°C  until  further  analysis.  In  center  2, 
vastus  lateralis  muscle  biopsies  were  taken  with  a 
Bergstrom needle and diaphragm biopsies were obtained 
by  sharp  dissection  when  possible.  Both  samples  were 
snap  frozen  and  stored  at  -80°C  for  further  analysis. 
Approximately 20 mg of frozen tissue was homogenized 
in 0.5 ml of lysis buffer (Triton - X100 (1%), NaCl (150 mM), 
Tris-HCl  (50  mM),  EDTA  (1  mM),  PMSF  (1  mM), 
protease inhibitors (Roche Diagnostics, Burgess Hill, UK); 
1 tablet per 10 ml), water to 10 ml) using a Powergen 125 
(Fisher Scientific, Loughbourgh, UK)) electric homogen-
izer.  Samples  were  left  on  ice  for  15  minutes  prior  to 
centrifuging at 13,000 rpm for 15 minutes. The super-
natant  was  removed,  and  protein  concentration  was 
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solution to known standards using the Lowry method. 
Samples were then stored at -80°C.
Approximately 20 mg of muscle was re-suspended in 
180 μl of low salt lysis buffer (10 mM HEPES, 10 mM 
KCl, 1.5 mM MgCl2, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM 
DTT,  0.5  mM  PMSF,  protease  inhibitors  (Roche  Diag-
nostics; 1 tablet per 10 ml)) and ground using a handheld 
homogenizer.  Samples  were  incubated  on  ice  for 
5 minutes before two cycles of freeze-thaw lysis. After a 
brief vortex, samples were centrifuged at 4,000 rpm for 
3 minutes. The supernatant was removed and the pellet 
(containing the nuclei) re-suspended in 40 μl high salt 
extraction buffer (20 mM HEPES, 420 mM NaCl, 1 mM 
EDTA, 1 mM EGTA, 25% glycerol, 1 mM DTT, protease 
inhibitors  (Roche  Diagnostics;  1  tablet  per  10  ml)). 
Samples were incubated on ice for 30 minutes with gentle 
mixing of the tubes every 5 to 10 minutes. Samples were 
centrifuged at 4,000 rpm for 5 minutes at 4°C. An aliquot 
of  supernatant  (containing  the  nuclear  proteins)  was 
stored at -80°C.
Protein from each sample (20 μg) was added to 3 μl of 
4 × loading buffer solution (0.5 M Tris-HCl pH 6.8, 20% 
glycerol,  4%  SDS,  0.05%  β-mercaptoethanol,  0.004% 
bromophenol  blue)  and  boiled  for  3  minutes.  Proteins 
were resolved using SDS-PAGE at 160V for 45 minutes. 
Proteins were transferred to a nitrocellulose membrane 
(80  mA  for  1  hour)  using  semi-dry  transfer  (Biorad, 
Hemel Hempstead, UK). Membranes were blocked with 
either  3%  bovine  serum  albumen/tris-buffered  saline 
(TBS) with Tween 20 (TBST; 0.05% Tween) overnight at 
4°C or with 5% milk/TBST for 1 hour at room tempera-
ture.  Incubation  with  primary  antibody  (1:1,000)  was 
carried out in either 3% bovine serum albumen/TBST or 
0.5%  milk/TBST  solution  at  room  temperature  for 
2 hours or overnight at 4oC. Membranes were washed 
with TBST and primary antibody binding detected using 
horseradish-peroxidase conjugated secondary antibodies 
(1:2,000  to  1:5,000;  anti-mouse,  anti-rabbit  (Upstate, 
Dundee,  UK)).  Specific  signal  was  detected  using  ECL 
reagent (GE Healthcare, Little Chalfont, UK) and expo-
sure on photographic film (Kodak). Films were scanned 
and densitometry values estimated using ImageJ (NIH) 
software. The primary antibodies used in the study were 
against  phos-CaMKII(Thr286),  FOXO1  and  FOXO3a 
(New England Biolabs, Hitchin, UK), Lamin A/C (Insight, 
Wembely,  UK),  alpha-skeletal  actin  (Novo  caestra, 
Newcastle,  UK)  and  calcium/calmodulin-dependent 
protein kinase (CaMK)II (BD Biosciences, Oxford, UK).
Total RNA was extracted from approximately 20 mg of 
muscle  using  TRIzol  (Invitrogen,  Paisley,  UK)  reagent 
according  to  the  manufacturer’s  directions.  The  RNA 
pellet was re-suspended in diethylpyrocarbonate-treated 
water and RNA concentration was determined using a 
Nanodrop  spectrophotometer  (LabTech  International, 
Ringmer, UK). RNA quality was assessed using 260/280, 
230/260  ratios  and  the  RNA  integrity  number  (RIN) 
score  from  the  BioAnalyzer  2100  instrument  (Agilent 
Technologies, Stockport, UK). Total RNA (3.5 μg) was 
reverse  transcribed  and  processed  according  to  the 
protocol provided by Affymetrix Inc. for the GeneChip 
Expression 3’ Amplification One-Cycle Target Labeling 
and Control Reagents kit (Affymetrix, High Wycombe, 
UK).  Reverse  transcription  and  second  strand  cDNA 
synthesis  were  followed  by  in  vitro  transcription  and 
biotinylation. Biotinylated cRNA products were cleaned 
up  using  columns  (Affymetrix).  The  quality  of  the 
biotinylated cRNA was assessed by Nanodrop (LabTech 
International, UK) and BioAnalyzer (Agilent Technol  o-
gies)  instruments  and  the  cRNA  was  then  fragmented 
according to Affymetrix protocols. Samples were hybrid-
ized  to  the  HGU-133plus2  GeneChip  array  (covering 
approximately 54,000 sequences). The raw data files can 
be accessed at the Gene Expression Omnibus using the 
ID [GEO:GSE18832].
For quantitative real time PCR (qRT-PCR), cDNA was 
prepared using 1 μg RNA, TaqMan reverse transcription 
reagents  (Applied  Biosystems,  Warrington,  UK)  and 
random hexamer primers (Applied Biosystems). Primers 
were designed to span introns using Primer Express 3.0 
software  (Applied  Biosystems)  and  constructed  by 
Invitrogen (Paisley, UK); primer sequences are detailed in 
Table S1 in Additional data file 1. Samples were run on an 
ABI  7900HT  Fast  Real-Time  PCR  system  (Applied 
Biosystems) in triplicates of 20 μl per well using SYBR 
Green PCR Master Mix (Applied Biosystems) as per the 
manufacturer’s  instructions.  Expression  levels  were 
normalized to ribosomal 18S RNA and results examined 
using the ΔCt method [17]. SPSS (SPSS Inc, Chicago, IL, 
USA)  or  GraphPad  (GraphPad  Software,  La  Jolla,  CA, 
USA)  statistical  software  was  utilized.  Student’s  two 
tailed t-test or one way ANOVA (analysis of variance) 
was used to compare means between groups. Log trans-
or  mation  was  used  when  appropriate.  Mann-Whitney 
was used for nonparametric analysis. Contingency tables 
were constructed where relevant and analyzed by Fisher’s 
exact test. Statistical significance was set at P < 0.05.
Microarray  data  were  analyzed  using  the  Microarray 
Suite  software  (MAS)  version  5.0  (Affymetrix).  To 
improve the accuracy of the gene to probe relationship, a 
custom chip definition file (CDF) [18] was used defining 
the  Affymetrix  probes  by  Ensembl  transcript  ID.  Data 
were  normalized  using  MAS5  and  robust  multi-array 
average [19]. Genes called absent on every array by the 
MAS5 software were filtered from the data and remain-
ing  genes  analyzed  using  the  quantitative  function  in 
significance  analysis  of  microarrays  (SAM)  [20]  imple-
mented in the Bioconductor suite [21]. Percentage weight 
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robustness of the approach, the limma package [22] in 
the  Bioconductor  suite  was  used  to  identify  genes  co-
varying  with  weight  loss  or  SI.  Both  SAM  and  limma 
generate  a  false  discovery  rate  (FDR)  [23].  All  genes 
identified  by  both  procedures  with  an  FDR  <10%  that 
covaried with weight loss were further examined. We also 
carried out a comparative microarray analysis [24,25] to 
examine  the  link  between  muscle  cachexia  and  other 
muscle physiological states. The top 20 most regulated 
genes by eccentric muscle damage [26], muscle obtained 
from intensive care unit patients [27] and in response to 
exercise training [24] were obtained from three published 
articles.  The  mean  values  for  these  highly  regulated 
marker  genes  for  these  physiological  states  were  then 
plotted using the patient values from the present study, 
where  patients  had  either  less  than  or  more  than  5% 
weight  loss.  Functional  annotation  of  these  genes  was 
carried out using Gene Ontology (GO) [28] utilizing the 
topGO  tool  [29]  in  the  Bioconductor  suite  along  with 
web-based Ingenuity Pathway Analysis [30]. For analysis 
of microarray data the Bioconductor suite [21] and the R 
language  for  statistics  (R  Development  Core  Team; 
version 2.7.1) were used.
The  gene-sets  (see  below)  identified  by  microarray 
analysis  were  used  in  further  investigation  of  the 
regulatory mechanisms using promoter analysis. For all 
genes  the  region  up  to  1,500  bp  upstream  of  the 
annotated gene start was used as the proximal promoter 
region. Both strands were then scanned with the JASPAR 
[31] matrices representing various mammalian transcrip-
tion factor binding sites (89 in total). A matrix specific 
threshold corresponding to 0.8 of the scoring range of the 
matrix  was  used  on  the  log-ratio  matrix.  All  log-ratio 
transformations were done using a zero order uniform 
background model and a pseudo-count of one to avoid 
zero-entries in the original JASPAR matrix. The number 
of hits per base-pair and the number of sequences with 
one  or  more  hits  were  registered  and  used  for  over-
representation statistical analysis. We used a background 
set of promoter sequences extracted in a similar manner 
from  the  ‘all  genes  expressed’  present/absent  call  in 
skeletal  muscle  from  this  array  technology  [24,27].  A 
sequence-specific  over-representation  was  calculated 
using  Fisher’s  exact  test  and  a  base-pair-specific  over/
under-representation  was  calculated  using  a  Z-score. 
Finally,  using  the  base-pair-specific  over-  and  under-
representation  values,  a  heatmap  was  generated  for 
visualization  purposes.  For  all  analyses  the  ASAP  [31] 
framework was used in conjunction with R.
Results
Subject characteristics
Fifty-nine  subjects  were  recruited  over  time  (7  controls 
and 52 patients with upper gastrointestinal cancer) from 
center 1 (Edinburgh). Patient demographics and anthro  po-
metric  characteristics  are  shown  in  Table  1.  Average 
weight loss for center 1 cancer patients was 8.9% (range 
-0.5  to  43.8%).  Compared  to  the  control  group,  cancer 
patients had significant weight loss (P < 0.001) and had a 
lower  BMI  (P  =  0.001).  The  controls  were  substantially 
younger (P = 0.009) and hence could not be used as a case-
control  comparison  group  for  the  molecular  profiling. 
Instead, gene expression was related to body mass status. 
WL cancer patients had a lower BMI (P = 0.010) than WS 
cancer patients. The Affymetrix GeneChip studies used a 
subset of 21 patients from the cohort in center 1, where 
high quality RNA was available at the time of gene-chip 
analysis (Table 2). BMI and mid-arm muscle circumference 
were  not  significantly  different  between  the  ‘Affymetrix 
cohort’ and the larger group of cancer patients. To validate 
the  findings  in  the  first  group  of  patients  (‘Affymetrix 
cohort’)  a  second  group  of  13  patients  with  esophageal 
cancer was recruited from an independent clinical center 
(center 2, Sweden). Patients of this group were similar to 
the cancer patients from center 1 (Table 1).
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Table 1. Clinical data for patients and control subjects 
from centers 1 and 2
  Center 1  Center 1  Center 2 
  no-cancer  patients  patients 
  (n = 7)  (n = 52)  (n = 13)
Male/female  5/2  34/18  12/1
Age (years)  51 (5.5)  66 (1.3)*  65 (1.5)*
% weight loss  0  8.9 (1.1)*  7.7 (2.0)*
BMI  30.6 (1.3)  25.5 (0.5)*  25.5 (1.2)
CRP  2.8 (0.7)  17.4 (4.4)  -
MAMC  25.9 (1.3)  24.4 (0.4)  -
Mean (standard error of the mean) values are presented. *P < 0.05 compared 
with center 1 control. Center 1: Edinburgh, UK; centre 2: Stockholm, Sweden.  
BMI: body mass index; CRP: C reactive protein; MAMC: mid-arm muscle 
circumference.
Table 2. Demographics of controls and cancer patients 
included in the Affymetrix analysis from centre 1
  No-cancer  Cancer patients   
  (n = 3)  (n = 18)  P
Male/female  2/1  12/6  -
Age (years)  45(2)  67(2)  <0.001
% weight loss  0  8.9(1.6)  <0.001
BMI  28.5(1.7)  24.4(0.8)  0.080
CRP  2.7(0.9)  19.7(8.1)  0.052
MAMC  23.8(1.7)  23.7(0.5)  0.960
Mean (standard error of the mean). BMI: body mass index; CRP: C reactive 
protein; MAMC: mid arm muscle circumference.
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loss in cancer (centre 1)
The microarray study was undertaken on rectus abdominis 
muscle from a subgroup of center 1 patients (Table 2). 
Hierarchical  and  k-means  clustering  were  undertaken 
with normalized data, using a gene list where those with 
a  low  standard  deviation  were  removed.  No  pattern 
emerged  from  this  analysis.  Using  the  probe-sets  that 
detect  atrogenes  (genes  reproducibly  detected  in  pre-
clinical models of cachexia), which we have previously 
demonstrated reliably change in human skeletal muscle 
sepsis  [27],  we  carried  out  hierarchical  and  k-means 
clustering. No pattern emerged from this analysis. Thus, 
our  first  attempted  analysis  did  not  yield  any  data  in 
support of pre-clinical studies [32] and also demonstrated 
that  muscle  cancer  cachexia  appears  distinct  from  the 
inflammation-driven skeletal muscle remodeling observed 
in the intensive care unit [27].
We then identified genes that varied with percentage 
weight  loss  using  the  quantitative  SAM  methodology 
[20]. In this multiple comparison corrected correlation 
analysis, the WS group contained both cancer patients 
and three non-cancer controls in order to identify bona 
fide cachexia associating genes. SAM identified 74 genes 
with  a  FDR  between  0  and  10%  (most  <5%  FDR)  that 
covaried positively with weight loss, and nine genes with 
a FDR between 0 and 10% (most <5% FDR) that covaried 
negatively with weight loss (Additional data file 2). Corre-
lation coefficients (R) for these 83 genes were generated 
using  Pearson’s  product  moment  correlation.  Positive 
coefficients ranged from 0.82 to 0.57 (P < 0.01), and for 
negatively correlating genes, R ranged from -0.74 to -0.65 
(P < 0.01). Each relationship was visually inspected by 
plotting the data.
Most of the genes correlating with weight loss had not 
been associated previously with cachexia in humans or 
animal models. Notably, FOXO transcription factors and 
the E3 ligases MURF1 and MAFbx were absent from this 
list. Simple cluster analysis revealed visual distinction of 
patients with <5% reported weight loss from those with 
>5%  reported  weight  loss  (Figure  1).  This  Affymetrix-
derived WL gene signature was technically validated by 
qRT-PCR  of  the  9  genes  (APCDD1,  CaMKIIβ,  EIF3I, 
HGS,  NUDC,  POLRMT,  SGK,  TIE1  and  TSC2).  Eight 
validated the microarray data, with only SGK expression 
being inconsistent with the Affymetrix analysis (Table 3 
and Figure 2; Supplemental figure 1 in Additional data 
file 3).
Candidate gene approach: analysis of FOXO transcription 
factors and components of the ubiquitin proteasome and 
autophagy pathways (centre 1)
While the microarray analysis did not yield any evidence 
for  proteolytic  pathways  being  upregulated,  as  seen  in 
intensive  care  unit  patients  with  the  same  gene  chip 
technology  [27],  investigation  of  components  of  these 
pathways was nevertheless undertaken in parallel to the 
gene-chip study. There was no difference in the nuclear 
level of FOXO1 and FOXO3a protein by western blotting 
when  patients  were  grouped  according  to  weight  loss. 
Expression  of  the  E3  ligases  MURF1  and  MAFbx  was 
examined  by  qRT-PCR  and  no  relationship  between 
mRNA expression and weight loss was found (data not 
shown).  The  autophagy-related  genes  GABRAPL1  and 
BNIP3  were  modestly  increased  in  WL  patients  com-
pared  to  WS  patients  or  controls  (fold  change  =  1.46 
versus 1.23 versus 1.07, respectively; P = 0.047). However, 
this P-value is unadjusted for the previous array analysis 
and  may  not  be  reliable.  Both  genes  demonstrated  a 
positive  association  with  systemic  inflammation 
(Table  S2  in  Additional  data  file  1  and  Figure  S2  in 
Additional data file 3).
Confirmation of genes associated with weight loss in 
cancer cachexia (center 2)
To  validate  the  WL  gene  signature  generated  in  rectus 
abdominis muscle from the center 1 cohort, nine genes 
were profiled using qRT-PCR (APCDD1, CaMKIIβ, EIF3I, 
HGS,  NUDC,  SKG,  POLRMT,  TIE1  and  TSC2)  in  two 
additional types of skeletal muscle obtained from cancer 
cachexia  patients.  The  significant  association  between 
CaMKIIβ and weight loss observed in rectus abdominis 
muscle from center 1 (R = 0.82, P = 0.01; Table 1) was 
reproduced (Figure 3a) in both vastus lateralis (R = 0.45, 
P = 0.06) and diaphragm muscle (R = 0.5; P = 0.03) from 
center  2  patients.  In  addition,  TIE1,  which  significantly 
correlated with weight loss in rectus abdominis (R = 0.67, 
P  =  0.01;  Table  1)  demon  strated  a  similar  (Figure  3b) 
relationship in vastus lateralis (R = 0.7, P = 0.003) but not 
in diaphragm. Given the changes observed for CaMKIIβ 
mRNA, the protein and phosphorylation level of CaMKII 
in all of the rectus abdominis muscle obtained in center 1 
was evaluated. Material from a total of 59 patients was 
available  at  the  time  the  analysis  was  carried  out 
(recruitment was ongoing beyond the time the microarray 
was  carried  out).  Western  blotting  for  both  CaMKII 
(Figure  3c)  and  phosphorylated  CaMKII  (Figure  3d) 
revealed  a  small  but  significant  (P  =  0.04  and  0.07, 
respectively) increase in WL patients compared with the 
expression determined in WS patients and controls.
Gene interaction and promoter analysis
In  order  to  generate  valid  pathway  or  ontological 
enrichment scores, it is essential to relate the modulated 
gene list with the genes detectably expressed in the tissue 
of interest and not with the genome as a whole (or the 
entire gene-chip content). The nature of the 83-gene WL 
gene  signature  was  explored  in  detail  using  GO.  The 
Stephens et al. Genome Medicine 2010, 2:1 
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Page 5 of 12highest ranked GO biological process activity from the 
DAVID webtool [33] was proline metabolism (P = 0.03). 
This was confirmed with the topGO [29] and GOStats 
[34] tools in Bioconductor. Proline metabolism has a role 
in collagen formation and increased collagen deposition 
has been noted in the muscle of cachectic cardiac failure 
patients  [35].  Network  analysis  using  Ingenuity  [30] 
revealed  several  interactions  that  involve  the  83  WL 
genes,  including  a  calmodulin  kinase  gene  network 
(Figure S3A in Additional data file 3), supporting the wet-
lab data and indicating that CaMKIIβ activation appears 
to  be  a  general  marker  of  muscle  wasting  in  human 
cancer  cachexia.  A  second  illustrative  pathway  (Figure 
S3B in Additional data file 3) features GLUT-4 (glucose 
transporter type 4) and interleukin-6, both of which are 
implicated  in  skeletal  muscle  metabolism  [36].  This 
Stephens et al. Genome Medicine 2010, 2:1 
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Figure 1. Cluster analysis identifies high and low weight loss groups. Using SAM and limma, 83 genes were identified as correlating with 
weight loss. Expression data from these genes were used to drive cluster analysis. This revealed two clusters of subjects; high weight loss (≥5%) and 
low weight loss (<5%).
-3 -2 -1 0 1 2
Page 6 of 12network  also  forms  numerous  connections  with  the 
glucocorticoid  and  androgen  receptors,  which  may  be 
involved in regulating skeletal muscle mass. It should be 
noted that despite using a back-ground gene expression 
file  in  Ingenuity  [30]  for  genes  only  detected  as  being 
expressed  in  human  skeletal  muscle  (approximately 
21,000  probe  sets,  based  on  MAS5  present-marginal 
calls) the Ingenuity network analysis still included genes 
that may not be robustly expressed and should be used in 
a qualitative hypothesis generation manner.
Gene sequence analysis of the WL gene-set was carried 
out to provide insight into the potential coordinators of 
this  expression  signature.  Interestingly,  FOXO  trans-
cription  binding  sites  tended  to  be,  if  anything, 
significantly  under-represented  in  the  human  cachexia 
WL  gene  set,  supporting  the  wet-lab  analysis.  Binding 
sites for SP1, ARNT.AHR (the hypoxia signaling partner) 
and TFAP2A (Transcription factor AP2-alpha or AP2) in 
particular,  were  over-represented  in  the  proximal 
promoters  of  the  WL-associated  genes  (Figure  S4  in 
Additional data file 3). The analysis further supports the 
idea that this list is distinct. Interestingly, the enriched 
TF binding sites may function as clock genes, controlling 
circadian  rhythm  [37].  Another  strategy  for  generating 
hypotheses for factors that might regulate a set of genes 
is  to  carry  out  comparative  expression  analysis  [25], 
where  two  physiological  studies  are  contrasted  using 
global gene chip data. In this case we present data that 
patients with greater weight loss do not appear to have a 
common overlap with muscle damage, muscle degenera-
tion in sepsis or muscle remodeling in exercise training 
(Figure 4).
Discussion
Cancer cachexia is thought to arise due to an imbalance 
of the anabolic and catabolic pathways partly driven by 
pro-inflammatory  cytokines  with  consequent  loss  of 
muscle mass (along with an accompanying loss of adipose 
tissue). In the present study, the expression of 74 genes 
correlated positively with weight loss in cancer cachexia 
Stephens et al. Genome Medicine 2010, 2:1 
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Table 3. Genes correlating with weight loss
  Center 1 (n = 21)  Center 2 (n = 13)
  Gene-chip  RT-qPCR
  CC rectus  CC rectus  Regression  CC vastus  Regression  CC  Regression
Gene  abdominis  abdominis  P-value  lateralis  P-value  diaphragm  P-value
APCDD1  -0.74  -0.51  0.03  0.26  NS  -0.20  NS
CAMk2B  0.82  0.50  0.01  0.45  0.06  0.50  0.03
EIF3I  0.64  0.50  0.02  0.10  NS  0.20  NS
HGS  0.7  0.67  0.00  0.17  NS  0.20  NS
NUDC  0.65  0.72  0.00  0.13  NS  0.0  NS
POLRMT  0.6  0.51  0.02  0.07  NS  0.0  NS
TIE1  0.67  0.53  0.01  0.70  0.003  0.0  NS
TSC2  0.69  0.47  0.03  0.40  0.1  0.0  NS
Significance analysis of microarrays (SAM) identified 82 genes correlating with weight loss. qRT-PCR validated eight of nine selected targets from this list (correlation 
coefficient (CC)). These eight genes were also examined in the cohort from center 2 using RNA extracted from anatomically distinct regions. For each gene the 
correlation coefficient from the Affymetrix data set is shown followed by the correlation coefficient for qRT-PCR and a P-value for this latter regression. NS: not 
significant.
Figure 2. qRT-PCR validates array-identified genes covarying 
with weight loss. For each of the genes validated by qRT-PCR 
Pearson correlation coefficients were generated for expression and 
percentage weight loss for both the Affymetrix data and the qRT-PCR 
data. All genes except SGK1 validated the array data. P-values for the 
correlations ranged from 0.03 to below 0.01. Yellow indicates positive 
correlation; blue indicates negative correlation.
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Page 7 of 12subjects  and  that  of  9  correlated  negatively  with  it. 
Validation of these genes by qRT-PCR provided excellent 
technical  confirmation  of  the  microarray  results. 
Biological validation of TIE1 and CaMKIIβ expression in 
an  independent  clinical  cohort  across  distinct  muscle 
groups, along with supportive network analysis, provides 
weight  to  the  claim  that  these  are  useful  markers  of 
cancer cachexia in humans. Contrary to evidence from 
animal models [7,8,11], there were no significant differ-
ences in expression of the E3 ligases MURF1 and MAFbx, 
while  FOXO  protein  activity  was  unchanged  in  WL 
compared to WS patients. These observations, combined 
with  the  array  and  promoter  analysis,  make  it  seem 
unlikely  that  FOXO  transcription  factors  regulate  the 
molecular  signature  of  cachexia  in  human  skeletal 
muscle,  challenging  the  relevance  of  the  pre-clinical 
literature in this field.
Novel human cancer cachexia markers
The significant correlation of CaMKIIβ mRNA expres-
sion with weight loss along with the small but significant 
change in protein levels in rectus abdominis suggests that 
CaMKIIβ  could  be  directly  involved  in  human  cancer 
cachexia.  CaMKIIβ  mRNA  also  increased  with  weight 
loss  in  vastus  lateralis  and  diaphragm.  The  serine/
threonine  kinase  CaMKII  holoenzyme  is  activated  by 
Ca2+/calmodulin,  leading  to  autophosphorylation  and 
maintenance of CaMKII activity even after the Ca2+ signal 
has  diminished  [38].  CaMKIIβ  is  expressed  in  skeletal 
muscle,  and  levels  of  the  protein  as  well  as  its 
phosphorylation  status  and  activity  increase  after 
exercise training [39]. The relationship between CaMKIIβ 
expression and cachexia observed in the present study 
implies  that  the  cancer  cachexia  profile  is  not  simply 
'physical  inactivity'.  In  addition,  it  has  recently  been 
demonstrated that Ca(2+)-CaM-eEF2K signaling may be 
responsible  for  acute  exercise-induced  inhibition  of 
muscle protein synthesis [40] and it is thus conceivable 
that chronic inappropriate activation of this ‘endurance 
training'-related signaling molecule [24] subdues normal 
maintenance of skeletal muscle mass. Additional factors 
that could modulate CaMKII activity include alterations 
in lipid metabolism [41].
The  significant  positive  correlation  for  TIE1  mRNA 
expression with weight loss in both the rectus abdominis 
and vastus lateralis muscle groups supports the idea that 
some chronic training-related genes are up-regulated in 
cachexia. In animal models TIE1 is required for normal 
vascular network development [42] while increased TIE1 
mRNA levels in human skeletal muscle in response to 
physiological  adaptation  to  exercise  training  has  been 
demonstrated  [43].  Whilst  the  ligands  and  signaling 
Stephens et al. Genome Medicine 2010, 2:1 
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Figure 3. CAMkIIβ and TIE1 correlate with weight loss in cancer cachexia. In order to validate the findings from the rectus abdominis, qRT-PCR 
was used to examine mRNA expression of (a) CAMkIIβ and (b) TIE1 in diaphragm (open circles) and vastus lateralis (closed circles) in a separate 
clinical cohort. Correlation plots for mRNA level against rate of weight loss are shown. Correlation coefficients were significant with P < 0.05. CAMkII 
protein and phospho-protein levels are increased in subjects with weight loss. (c) Protein levels of CAMkII and (d) phosphoCAMkII were assessed 
in the rectus abdominis muscle from center 1 subjects by western blot. Intensity levels were normalized against alpha-skeletal actin and the mean 
ratio of CAMkII/actin or phosphoCAMkII (pCAMkII)/actin are shown for subjects with less than (black) or more than (white) 5% weight loss. *P-value 
<0.05, one-sided Mann Whitney test; n = 59. Error bars represent SEM.
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Page 8 of 12pathways of TIE1 are poorly understood, this receptor 
can interact with phosphoinositide 3-kinase and lead to 
phosphorylation and activation of Akt, protecting cells 
from  apoptosis  [44].  In  functional  terms,  the 
up-regulation  of  TIE1  may  therefore  represent  a 
protective  mechanism  to  oppose  apoptosis  of  some 
components of skeletal muscle tissue, for example, the 
vascular endo  the  lium. TIE1 has also recently been linked 
to  an  in  vitro  endothelial  inflammatory  response  [45] 
while an inflam  matory gene signature has been shown to 
develop through  out surgical procedures in muscle [46]; 
thus,  it  could  be  argued  that  some  component  of  our 
gene signa  ture may be related to surgery. However, all 
biopsies were taken at the earliest point in surgery after 
the initial incision.
Furthermore, the correlation of TIE1 expression with 
weight loss and the lack of any further appreciable inflam-
matory signature would argue against this possibility. In 
addition, there was no evidence that the muscle profile 
was  that  of  damage  or  that  observed  with  systemic 
inflam  mation  associated  with  multiple  organ  failure 
(Figure  4).  It  is  also  notable  that  (other  than  TIE1, 
CaMKII,  CTSA  and  PRODH)  the  WL  gene  signature 
does  not  share  similarities  with  the  approximately 
500-gene endurance exercise training gene signature [24], 
suggesting that the reason for elevated TIE1 and CaMKIIβ 
remains to be determined. It may be inappropriate partial 
muscle  activity  signaling  but  clearly  is  not  simply 
increased  muscle  usage  (however  unlikely  that  might 
have seemed in such patients). However, the increased 
CaMKIIβ  mRNA  levels  associated  with  weight  loss 
across a range of muscle tissues imply that these muscle 
groups develop dysregulation of calcium sensing or are 
burdened by greater loading in the face of failing muscle 
function connected with, for example, loss of contractile 
machinery or impaired energy metabolism [47].
Finally, recent work has clarified two potential calcium-
independent  activation  pathways  for  CaMKII.  Genera-
tion  of  reactive  oxygen  intermediates  can  increase  or 
prolong CaMKII activity, perhaps through inhibition of 
protein phosphotases that normally limit CaMKII activa-
tion  [48].  CaMKII  has  also  been  implicated  in  muscle 
adaptation through phosphorylation of HDAC5 leading 
to  MyoD/MEF2-driven  differentiation  of  muscle  cells 
[49]. It is plausible, therefore, that CaMKII activation is a 
compensatory  strategy  in  the  face  of  failing  protein 
synthesis.  Alternatively,  the  CaMKIIβ  response  may 
indicate  failure  of  calcium  homeostasis,  a  factor  that 
would also activate proteolytic activities such as calpains 
and  caspases  [50,51].  It  is  thus  possible  that  CaMKIIβ 
activa  tion occurs at an early stage of cachexia in humans, 
providing an early 'read-out' on altered calcium handling.
Human versus animal-model cancer cachexia markers and 
study limitations
Given the robust increase in expression of the E3 ligases 
reported previously in various animal models of cachexia 
[7,8,32],  it  is  surprising  that  neither  microarray  nor 
Figure 4. Gene expression signatures demonstrate lack of 
relationship between weight loss and muscle damage, muscle 
sepsis and exercise training status. The top 20 most regulated 
genes by (a) eccentric muscle damage, (b) muscle obtained from 
intensive care unit patients and (c) in response to exercise training 
were obtained from three published articles (see Methods). The 
mean values for these selected genes were then plotted for patients 
in the present study that had either less than or more than 5% 
weight loss. As can be observed, no single gene, for each of these 
‘comparative’ conditions, was differentially expressed; thus, the gene 
expression profile of cancer cachexia does not resemble muscle 
damage, sepsis-induced degeneration or exercise training status. 
Error bars represent SEM.
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Page 9 of 12qRT-PCR detected any regulation of MuRF1 and MAFbx. 
Furthermore,  the  83-gene  WL  gene  signature  bore  no 
resemblance to the Atrogene gene expression signature 
[27,32]  generated  using  gene-chips.  This  is  not  due  to 
gene-chip technology being unable to establish parallels 
between animal models and humans, as it has previously 
been  demonstrated  that  gene  expression  in  skeletal 
muscle of intensive care unit patients resembles, in part, 
that found in these animal models [27,32]. Indeed, results 
of E3 ligase expression analysis from other human models 
of  cachexia  have  been  contradictory.  Studies  including 
patients  following  bed  rest,  amputation  for  vascular 
disease, limb immobilization, chronic obstructive pulmo-
nary  disease,  amyotrophic  lateral  sclerosis  and  ageing 
have demonstrated both increased and decreased expres-
sion of MuRF1 and MAFBx [52-56]. This would suggest 
that the ubiquitin E3 ligases do not play the same role in 
human cancer cachexia as that previously demonstrated 
in animal and cell studies. In lung cancer patients with 
mean weight loss of 2.9%, there was no evidence of UPP 
activation  [57]  while  other  human  studies  in  patients 
with gastric cancer and mean weight losses of 5.2% and 
5.6% have shown increases in components of the UPP 
[58,59]. In the present study we could not find any support 
for  this  finding,  despite  similar  degrees  of  cachexia. 
However,  cancer  cachexia  encompasses  a  spectrum 
progressing  from  early  weight  loss  through  to  severe 
muscle  wasting.  The  prominence  of  the  individual 
proteo  lytic pathways at different time points along this 
spectrum is yet to be determined and one must keep in 
mind that during severe tissue wasting, both breakdown 
(and of course synthesis) may well be reduced with the 
net balance between the two widened.
A role for autophagy in human cancer cachexia has not 
been investigated extensively. Increased cathepsin D and 
acid  phosphatase  activity  has  been  demonstrated  in 
patients with varying tumor types and degrees of weight 
loss,  suggesting  that  increased  lysosomal  activity  may 
contribute  to  the  development  of  cachexia  [60].  More 
recently, lung cancer patients undergoing resection were 
shown to have increased levels of cathepsin B mRNA in 
skeletal muscle compared with controls [57]. The analyses 
examined GABARAPL1 and BNIP3. GABARAPL1 is an 
Atg8  homologue  important  in  the  formation  of  the 
autophagosome [61] and BNIP3 has been found to play a 
predominant  role  in  induction  of  autophagy  in  rodent 
skeletal  muscle  [11].  Autophagy  can  be  induced  by 
starvation of amino acids, which may explain the modest 
increase in BNIP3 and GABARAPL1 in patients with SI 
where the acute phase response is activated (mobilizing 
amino acid from muscle to liver for consumption) and 
where food intake may be reduced due to anorexia or 
dysphagia. However, no relationship was found between 
these genes and patient weight loss.
A limitation of the current study is that we focus on 
changes in total body mass and this does not tell us about 
the  relative  contributions  from  lean  body  mass  and 
adipose  tissue.  Our  muscle  gene  expression  clustering 
results indicate, however, that there is a skeletal muscle 
molecular signature that reflects changes in whole body 
mass and it is hard to conceive that this is not somehow 
reflecting  the  changes  in  the  muscle  tissue.  A  further 
consideration  is  adequate  control  for  confounding 
parameters, such as inflammation, damage and physical 
activity. While these are difficult to directly control, we 
produced an analysis to suggest that such processes were 
unrelated  to  our  new  human  muscle  cancer  cachexia 
signature (Figure 4).
Conclusions
Human cancer cachexia is a chronic process and weight 
loss  is  not  as  rapid  and  generally  not  as  severe  as  the 
acute muscle wasting observed in animal models. Thus, 
the physiological regulators are most likely very distinct 
in each scenario. We found increased expression of two 
‘endurance exercise’-activated genes, CaMKIIβ and TIE1, 
across different muscle groups in human cancer cachexia. 
Whether these could contribute to a reduction in protein 
synthesis remains to be ascertained.
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